Adalimumab biosimilar in inflammatory bowel disease

The use of biosimilars of monoclonal antibodies against TNFα is one of the key pillars in the treatment of inflammatory bowel disease (IBD), and, more generally, in all immune-mediated diseases. In relation to IBD, the Biosimilar Council estimated that the increasing availability of biosimilars has provided a potential saving between US53 and 06 billion in western Europe and the USA between 2015 and 2020. 1 Biosimilars CouncilBiosimilar...